Allergan plc (NYSE:AGN) – Stock analysts at Jefferies Financial Group issued their Q1 2019 earnings per share (EPS) estimates for shares of Allergan in a report released on Monday, April 15th. Jefferies Financial Group analyst D. Steinberg anticipates that the company will post earnings of $3.55 per share for the quarter. Jefferies Financial Group currently has a “Hold” rating and a $144.95 target price on the stock. Jefferies Financial Group also issued estimates for Allergan’s Q2 2019 earnings at $4.20 EPS, Q3 2019 earnings at $4.08 EPS, Q4 2019 earnings at $4.56 EPS, FY2019 earnings at $16.38 EPS, FY2020 earnings at $17.16 EPS, FY2021 earnings at $17.80 EPS, FY2022 earnings at $18.12 EPS and FY2023 earnings at $18.82 EPS.
Allergan (NYSE:AGN) last released its earnings results on Tuesday, January 29th. The company reported $4.29 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $4.15 by $0.14. The firm had revenue of $4.08 billion during the quarter, compared to analyst estimates of $4 billion. Allergan had a positive return on equity of 8.18% and a negative net margin of 32.28%. Allergan’s revenue was down 5.7% compared to the same quarter last year. During the same period last year, the business posted $4.86 earnings per share.
A number of other brokerages also recently issued reports on AGN. Leerink Swann set a $217.00 price target on Allergan and gave the stock a “buy” rating in a report on Thursday, March 7th. Credit Suisse Group downgraded Allergan from an “outperform” rating to a “neutral” rating and decreased their price target for the stock from $197.00 to $161.00 in a report on Thursday, January 31st. ValuEngine downgraded Allergan from a “sell” rating to a “strong sell” rating in a report on Thursday, April 4th. Zacks Investment Research downgraded Allergan from a “hold” rating to a “sell” rating in a report on Thursday, January 3rd. Finally, TheStreet downgraded Allergan from a “c” rating to a “d+” rating in a report on Tuesday, January 29th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and fourteen have issued a buy rating to the stock. Allergan has an average rating of “Hold” and a consensus price target of $188.14.
Shares of NYSE AGN opened at $143.58 on Tuesday. The stock has a market cap of $48.21 billion, a price-to-earnings ratio of 8.60, a price-to-earnings-growth ratio of 1.16 and a beta of 1.34. The company has a quick ratio of 0.98, a current ratio of 1.13 and a debt-to-equity ratio of 0.35. Allergan has a 1 year low of $125.84 and a 1 year high of $197.00.
Several institutional investors have recently bought and sold shares of the company. Sciencast Management LP purchased a new stake in shares of Allergan in the 1st quarter valued at about $422,000. Ridgewood Investments LLC purchased a new stake in shares of Allergan in the 1st quarter valued at about $255,000. Virtu Financial LLC purchased a new stake in shares of Allergan in the 1st quarter valued at about $1,851,000. Shorepoint Capital Partners LLC purchased a new stake in shares of Allergan in the 1st quarter valued at about $777,000. Finally, Mercer Global Advisors Inc. ADV purchased a new stake in shares of Allergan in the 1st quarter valued at about $2,061,000. 80.65% of the stock is owned by institutional investors and hedge funds.
In other news, Chairman Brent L. Saunders bought 1,760 shares of Allergan stock in a transaction dated Thursday, March 7th. The stock was acquired at an average cost of $143.67 per share, with a total value of $252,859.20. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 0.08% of the stock is currently owned by insiders.
Allergan announced that its board has authorized a stock buyback plan on Tuesday, January 29th that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the company to repurchase up to 4.1% of its shares through open market purchases. Shares repurchase plans are often a sign that the company’s board believes its shares are undervalued.
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products.
Featured Story: Blue-Chip Stocks
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.